ANTIOS THERAPEUTICS
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
ANTIOS THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2018-01-01
Address:
Atlanta, Georgia, United States
Country:
United States
Website Url:
http://www.antiostherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
200.4 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Amazon SSL By Default Person Schema Microsoft Exchange Online Office 365 Mail Gravatar Profiles Microsoft Azure DNS
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Antharis Therapeutics
Antharis Therapeutics is a biopharmaceutical company developing therapies for unmet medical needs.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Ocera Therapeutics
Ocera Therapeutics is a biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Silverback Therapeutics
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
EPIQ Capital Group
EPIQ Capital Group investment in Series B - Antios Therapeutics
Altium Capital
Altium Capital investment in Series B - Antios Therapeutics
Domain Associates
Domain Associates investment in Series B - Antios Therapeutics
Heartland Healthcare Capital
Heartland Healthcare Capital investment in Series B - Antios Therapeutics
Pontifax
Pontifax investment in Series B - Antios Therapeutics
GRA Venture Fund
GRA Venture Fund investment in Series B - Antios Therapeutics
GordonMD Global Investments
GordonMD Global Investments investment in Series B - Antios Therapeutics
Avego Bioscience Capital
Avego Bioscience Capital investment in Series B - Antios Therapeutics
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series B - Antios Therapeutics
Amzak Health Investors
Amzak Health Investors investment in Series B - Antios Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-10 | Antios Therapeutics Appoints Catherine Coffey Ross as VP, Medical Affairs |
Official Site Inspections
http://www.antiostherapeutics.com Semrush global rank: 5.26 M Semrush visits lastest month: 1.47 K
- Host name: 208.82.16.57
- IP address: 208.82.16.57
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Antios Therapeutics"
Antios Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is …See details»
Antios Therapeutics - Advancing Tomorrow & Therapies Today
Discover advanced osteoporosis treatments and bone health solutions at Antios Therapeutics. Our innovative therapies aim to improve bone density and enhance your quality of life.See details»
Antios Therapeutics Company Profile | Management and
[email protected]: Antios Therapeutics Top Competitors. Company Employees Revenue Top technologies; Chromis Therapeutics Inc. 9: $1.6 M: Arno Therapeutics Inc. 4: …See details»
Antios Therapeutics - LinkedIn
Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is ...See details»
- Drug pipelines, Patents, Clinical trials - Synapse
Explore Antios Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 6 clinical trials, 24 news, and 1 literature, Drug:ATI-1428, ATI-2173 ...See details»
Antios Therapeutics Company Overview, Contact Details
Viral Disease Focus Antios Therapeutics specializes in innovative therapies for viral diseases, with a lead oral drug candidate targeting potentially curative treatment for HBV infections. This …See details»
Antios Therapeutics CEO and Key Executive Team | Craft.co
Antios Therapeutics's President and Chief Executive Officer is Greg Mayes. Other executives include Patrick Higgins, Director; Doug Mayers, Chief Medical Officer and 10 others. See the …See details»
Hep B biotech Antios closed after FDA hold proved …
Sep 22, 2023 Assembly also ended its quest for a functional cure of hepatitis B with vebicorvir in July 2022 after lackluster data showed the core inhibitor was unlikely to succeed. The company pivoted to ...See details»
Antios Therapeutics Announces Agreement with …
Nov 15, 2021 For more information, please visit www.antiostherapeutics.com. About IRBM IRBM is a drug hunting company working primarily as an innovative contract research organization across all aspects of drug discovery and early …See details»
Antios Therapeutics - Craft
Antios Therapeutics is a biopharmaceutical company that specializes in therapies for hepatitis B virus (HBV) and other viral diseases. It develops active site polymerase inhibitor nucleotide …See details»
Antios Therapeutics and Arbutus Biopharma Announce First …
Dec 14, 2021 MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) …See details»
Antios Therapeutics and Assembly Biosciences Announce Clinical ...
Oct 19, 2021 MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) …See details»
Antios Therapeutics Announces Oral Presentations on ATI-2173, …
ATI-1428 and ATI-1645 were acquired by Antios in November of 2021 from San Raffaele Hospital (OSR), Istituto Nazionale Genetica Molecolare (INGM), and IRBM/Promidis, a collaboration of …See details»
Antios Therapeutics to acquire fourth-generation HBV capsid
For more information, please visit www.antiostherapeutics.com www.antiostherapeutics.com. About IRBM. IRBM is a drug hunting company working primarily as an innovative contract …See details»
Antios Therapeutics' ATI-2173 Demonstrates Suppression of
The World Health Organization estimates that up to 300 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2 million people in the …See details»
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to ...
MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic …See details»
Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral …
Jun 23, 2021 Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral Activity and Evidence of Off-Treatment Sustained Viral Suppression in Chronic HBV PatientsSee details»
Antios Therapeutics' ATI-2173 Demonstrates Suppression of …
Jun 25, 2022 The World Health Organization estimates that up to 300 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately two million …See details»
Antios Therapeutics Announces Agreement with IRBM, INGM and
For more information, please visit www.antiostherapeutics.com www.antiostherapeutics.com. About IRBM IRBM is a drug hunting company working primarily as an innovative contract …See details»